General MedicationsSUBCUTANEOUSStandard
YEZTUGO
LENACAPAVIR
Standard Dose
463.5MG/1.5ML(309MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview YEZTUGO is listed in Drugs@FDA under application 220018 (NDA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient LENACAPAVIR Form and strength SOLUTION;SUBCUTANEOUS - 463.5MG/1.5ML(309MG/ML) Sponsor GILEAD SCIENCES INC Submission history Latest submission status date: 2025-06-18 00:00:00.
Structured Monograph
Clinical summary
Approval overview YEZTUGO is listed in Drugs@FDA under application 220018 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient LENACAPAVIR Form and strength SOLUTION;SUBCUTANEOUS - 463.5MG/1.5ML(309MG/ML) Sponsor GILEAD SCIENCES INC Submission history Latest submission status date: 2025-06-18 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.